Dr. Daniel Wynn MD
Director of Clinical Research, CONSULTANTS IN NEUROLOGY LTD
Member of the Healthcare Council
Council Member Biography
Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke, chronic pain and migraine, epilepsy, Parkinson's disease, sleep disorders, attention deficit hyperactivity disorder (ADHD), and others. Dr. Wynn serves on the Clinical Advisory Committee of National Multiple Sclerosis Society and is Co-Director of Consultants in Neurology Multiple Sclerosis Center. He is a member of numerous professional organizations including Alpha Omega Alpha Honor Medical Society, American Academy of Neurology, and American Medical Association. Dr. Wynn is widely published in The New England Journal of Medicine, Neurology, Annals of Neurology, Lancet, Journal of the AMA, Pediatrics, Mayo Clinic Proceedings, and presents frequently at meetings in the US and overseas. (This is me - Update Profile)
Employment History
- 1988 - Unspecified
- Director of Clinical Research, CONSULTANTS IN NEUROLOGY LTD
GLG NewsSM Analyses by Daniel Wynn(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Fampridine-SR -- anxiously awaited new MS therapeutic
June 2, 2009
Acorda’s Fampridine-SR Gets Priority Review | phoenix.corporate-ir.net
A major unmet need in the treatment of Multiple Sclerosis is a medication to increase walking ability. Since disease modifying therapies have only been available for 16 years, MS starts at a mean age of 29, and the disease has only a minimal effect at shortening lifespan, the majority of MS patients presently have progressive forms of MS. Ten percent have primary progressive disease, progressive from the onset, and others, start with relapsing remitting MS, and progress after approximately 15 years to progressive illness. In the early years of progressive MS, patients loose the ability to walk, hence the prior motto of the National MS Society, "MS, the great crippler of young adults." FAMPRIDINE SR IS THE FIRST MEDICATION FOUND TO IMPROVE MS PATIENTS ABILITY TO WALK. Standard disease modifying agents, the interferons (Avonex, Betaseron, Rebif), Copaxone and Tysabri, decrease relapse rate and may slow progression, however do not improve one's ability to walk.
-
NUVIGIL for Jet Lag -- An Important Broad New Indication for Cephalon
June 2, 2009
Cephalon to apply for FDA approval for Nuvigil for jet lag | www.reuters.com
NUVIGIL, Cephalon's single isomer longer effective half-life follow-up product to Provigil is coming to market only after careful strategic planning. While extremely successful, Provigil, a unique wake promoting agent, suffered in many ways. When introduced, it had only FDA approval for narcolepsy, a relatively uncommon, yet severe sleep disorder. Sales increased markedly when Provigil became approved for other common conditions associated with excessive daytime sleepiness (EDS), treated obstructive sleep apnea with residual EDS and sleep wake shift disturbance (SWSD). If approved for Jet Lag, there is the promise that Nuvigil will become available for an increasing enlarging marketplace.
-
"Tamper-Proof" -- A Significant Gain to Whom??
November 17, 2008
FDA Asks if Pain Pill Is Tamper-Proof | online.wsj.com
Abuse resistant long acting narcotics offer benefit as they are less desirable to those who might wish a quick high via snorting, injecting crushed time-release narcotic. Unfortunately, given the higher cost than long acting generics and increased pressure on physicians to prescribe generics, expect pick up in the marketplace (assuming approval) to be slow.
-
Novartis and Multiple Sclerosis: A Major Commitment
June 5, 2008
Extavia® approved in E.U for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis | www.asia-manufacturing.com
Extavia, Novartis' brand of interferon beta 1b, has been approved for the treatment of multiple sclerosis by the European Union. With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009. While essentially identical to Bayer's Betaferon interferon beta 1b, and similar to EMD Serono's Rebif and Biogen's Avonex, Extavia does not offer a new therapy to MS patients, simply a new face. With this launch, Novartis presumably hopes to work closer to key opinion leaders in multiple sclerosis, allowing an accelerated launch of Fingolimod.
-
Abbott's ABT-089 --Much More than a Treatment for ADHD
June 2, 2008
Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD. The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.
Leading institutions connect with Daniel Wynn through GLG
GLG Study Groups with Daniel Wynn(?)
| Study Group Name | No. Members |
|---|---|
| Neurologists | 1861 |
| Neurologists (US) | 1079 |
| Physicians who Treat Insomnia (US) | 546 |
| Pain Physicians (US) | 538 |
| Physicians who Treat Diabetes (US) | 466 |
GLG Live Meetings with Daniel Wynn(?)
Daniel Wynn has not participated in any GLG Live Meetings.